Avirmax Inc. To Present At The ARVO Frontiers In Ocular Gene Therapy Research Conference
Avirmax's Chief Executive and Scientific Officer, Dr. Shengjiang Shawn Liu, Ph.D., will chair the upcoming session of " Acceleration of AAV Gene Therapy for Ocular Diseases: Improving Delivery and ...
manilatimes6h
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology ...
FiercePharma7h
Ascend continues to climb with deal that elevates the CDMO’s US footprint
Ascend Advanced Therapies, which has been on an expansion tear since debuting three years ago, inked a deal with EW ...
stocknews8d
3 Biotech Stocks Predicted to Surge on Medical Innovation
Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...
Yahoo Finance2d
IND for ATA-200, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), cleared to proceed by FDA
The multicenter Phase1b open-label dose escalation study (NCT05973630) will evaluate safety, pharmacodynamics, efficacy, and immunogenicity in children receiving intravenous ATA-200, a single-dose ...
Business Insider6d
Rocket Pharmaceuticals: Strong Buy Rating Backed by Promising AAV and LV Franchise Developments and Solid Financial Position
Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...
manilatimes1d
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...
eLife2d
Endophilin A1 facilitates organization of the GABAergic postsynaptic machinery to maintain excitation-inhibition balance
This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...
Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients with Osteoarthritis (OA) of the Knee
Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent ...
PharmTech1d
Ascend Advanced Therapies Expands US Footprint in New Partnership
Ascend’s fill/finish capacity in the US will also be expanded. “We founded Ascend with a vision to quilt together the best operators and technologies within the advanced manufacturing field. The ...
The Pharma Letter13d
Roche will aim to tackle gene therapy challenges through Dyno deal
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to ...
GEN21d
Roche, Dyno Launch $1B+ AAV Gene Therapy Vector Collaboration
Roche will apply Dyno Therapeutics’ engineered adeno-associated virus (AAV) capsid platform to develop next-generation AAV vectors for gene therapies targeting unspecified neurological diseases ...